教你如何选购汽车防盗器.pptxVIP

下载本文档

1
0
约4.47千字
约 70页
2021-09-13 发布于河北
举报
版权申诉

教你如何选购汽车防盗器.pptx

1、原创力文档（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。。
2、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击这里二次下载。
3、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。
4、该文档为VIP文档，如果想要下载，成为VIP会员后，下载免费。
5、成为VIP后，下载本文档将扣除1次下载权益。下载后，不支持退款、换文档。如有疑问请联系我们。
6、成为VIP后，您将拥有八大权益，权益包括：VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
7、VIP文档为合作方或网友上传，每下载1次，网站将根据用户上传文档的质量评分、类型等，对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档

Vaccines and Related Biological Products Advisory Committee (VRBPAC)May 21, 2002Prevnar?, Pneumococcal Conjugate Vaccine 7-valent, for the Prevention of Acute Otitis Media?;Review Team;Proposed Indication;Regulatory Background;Global Issues;Comments from Medical Community:Correspondence to New England Journal of Medicine;Clinical Studies Reviewed;Outline of FDA Presentation;Finnish OM Study—Primary Objective ;Finnish OM Study—Secondary Objectives ;Finnish OM Study: Elements of the Study Design;Finnish OM Study: Vaccine Schedule and Concurrent Immunizations;Finnish OM study ;Finnish OM Study:Clinical Definition of Acute Otitis Media ;Finnish OM Study: AOM Efficacy Endpoints;Finnish OM Study- Definition of Primary Endpoint ;Finnish OM Study:Primary Endpoint Definition ;Finnish OM Study-Analysis of Primary Endpoint;Finnish OM Study-Definitions of Follow-up Periods;Finnish OM Study:Selected Population Characteristics ;Finnish OM Study-Primary Analysis, AOM due to Vaccine Serotypes;Finnish OM Study-AOM due to Individual Vaccine Serotypes, (Intent-to-treat);Finnish OM Study-Secondary Analyses, First and Subsequent AOM Episodes due to Vaccine Serotypes;Finnish OM Study-Efficacy for All Culture-Confirmed Pneumococci, Regardless of Serotype;Finnish OM Study-Efficacy for Vaccine-Related Serotypes;Finnish OM Study-AOM due to Individual Vaccine-Related Serotypes, (Intent-to-treat);Finnish Otitis Media Study-Efficacy for Vaccine-Unrelated Pneumococcal Serotypes;Finnish Otitis Media Study-Efficacy for Recurrent AOM *;Finnish Otitis Media Study-Efficacy for Other Planned Analyses;Finnish OM Study-Efficacy for Nasopharyngeal Carriage of Vaccine Serotypes (per protocol);Finnish OM Study—Serum Geometric Mean Antibody Concentration (GMC) After 3rd and 4th Doses;Finnish OM Study—Serum Antibody Concentrations (GMC) and Serotype-Specific Efficacy;Finnish Otitis Media Study—Invasive Disease Due to Pneumococcus;Finnish Otitis Media Study: Review Issues